The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment Option Overview ¹

Added text ² about the value of adjuvant therapy in patients with stage II colon cancer (cited International Multicentre Pooled Analysis of B2 Colon Cancer Trials Investigators as reference 10, Gill et al. as reference 11, and Mamounas et al. as reference 12).

Stage IV and Recurrent Colon Cancer ³

Added text ⁴ about additional drug combinations including the CAPOX regimen, the FUFOX regimen, the FUOX regimen, and the XELOX regimen.

Added text ⁵ about the Bolus, Infusional, or Capecitabine with Camptosar-Celecoxib trial that evaluated different irinotecan-based regimens in patients with previously untreated metastatic colorectal cancer and concluded that FOLFIRI is preferred (cited Fuchs et al. as reference 58 and level of evidence 1iiDiii).

Added text ⁶ about randomized phase III trials that addressed the equivalence of oral FUOX substituting for 5-FU and evaluated FUOX versus CAPOX (cited Diaz-Rubio et al. as reference 59 and level of evidence 1iiDiii and Porschen et al. as reference 60).